Literature DB >> 32482842

Clinical and radiographic course of arrested cerebral adrenoleukodystrophy.

Eric J Mallack1, Stephanie van de Stadt1, Paul A Caruso1, Patricia L Musolino1, Reza Sadjadi1, Marc Engelen1, Florian S Eichler2.   

Abstract

OBJECTIVE: To gain insight into the natural history of arrested cerebral adrenoleukodystrophy (CALD) by quantifying the change in Neurologic Function Score (NFS) and Loes Score (LS) over time in patients whose cerebral lesions spontaneously stopped progressing.
METHODS: We retrospectively reviewed a series of 22 patients with arrested CALD followed longitudinally over a median time of 2.4 years (0.7-17.0 years). Primary outcomes were change in radiographic disease burden (measured by LS) and clinical symptoms (measured by NFS) between patients who never developed a contrast-enhancing lesion (gadolinium enhancement (GdE)- subgroup) and those who did (GdE+ subgroup). Secondary analyses comparing patterns of neuroanatomic involvement and lesion number, and prevalence estimates, were performed.
RESULTS: Cerebral lesions were first detected at a median age of 23.3 years (8.0-67.6 years) with an initial LS of 4 (0.5-9). NFS was 0.5 (0-6). Overall change in NFS or LS per year did not differ between subgroups. No patients who remained GdE- converted to a progressive CALD phenotype. The presence of contrast enhancement was associated with disease progression (r s = 0.559, p < 0.001). Four patients (18.2%) underwent step-wise progression, followed by spontaneous resolution of contrast enhancement and rearrest of disease. Three patients (13.6%) converted to progressive CALD. Nineteen patients (86.4%) had arrested CALD at the most recent follow-up. The prevalence of arrested CALD is 12.4%.
CONCLUSION: Arrested CALD lesions can begin in childhood, and patients are often asymptomatic early in disease. The majority of patients remain stable. However, clinical and MRI surveillance is recommended because a minority of patients undergo step-wise progression or conversion to progressive CALD.
© 2020 American Academy of Neurology.

Entities:  

Year:  2020        PMID: 32482842     DOI: 10.1212/WNL.0000000000009626

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  6 in total

1.  A Longitudinal Analysis of Early Lesion Growth in Presymptomatic Patients with Cerebral Adrenoleukodystrophy.

Authors:  E J Mallack; G Askin; S van de Stadt; P A Caruso; P L Musolino; M Engelen; S N Niogi; F S Eichler
Journal:  AJNR Am J Neuroradiol       Date:  2021-09-09       Impact factor: 4.966

2.  Presymptomatic Lesion in Childhood Cerebral Adrenoleukodystrophy: Timing and Treatment.

Authors:  Eric James Mallack; Keith P Van Haren; Anna Torrey; Stephanie van de Stadt; Marc Engelen; Gerald V Raymond; Ali Fatemi; Florian S Eichler
Journal:  Neurology       Date:  2022-05-24       Impact factor: 11.800

3.  Glycoprotein nonmetastatic melanoma protein B (GNMPB) as a novel biomarker for cerebral adrenoleukodystrophy.

Authors:  Leyla A Taghizadeh; Carina J King; David R Nascene; Ashish O Gupta; Paul J Orchard; LeeAnn Higgins; Todd W Markowski; Erin E Nolan; Justin W Furcich; Troy C Lund
Journal:  Sci Rep       Date:  2022-05-14       Impact factor: 4.996

4.  MRI surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: Meta-analysis and consensus guidelines.

Authors:  Eric J Mallack; Bela R Turk; Helena Yan; Carrie Price; Michelle Demetres; Ann B Moser; Catherine Becker; Kim Hollandsworth; Laura Adang; Adeline Vanderver; Keith Van Haren; Maura Ruzhnikov; Joanne Kurtzberg; Gustavo Maegawa; Paul J Orchard; Troy C Lund; Gerald V Raymond; Molly Regelmann; Joseph J Orsini; Elisa Seeger; Stephan Kemp; Florian Eichler; Ali Fatemi
Journal:  J Inherit Metab Dis       Date:  2021-01-09       Impact factor: 4.982

5.  Low donor chimerism may be sufficient to prevent demyelination in adrenoleukodystrophy.

Authors:  Takahiro Ikeda; Yuta Kawahara; Akihiko Miyauchi; Hitomi Niijima; Rieko Furukawa; Nobuyuki Shimozawa; Akira Morimoto; Hitoshi Osaka; Takanori Yamagata
Journal:  JIMD Rep       Date:  2021-11-17

6.  Gait Difficulties and Postural Instability in Adrenoleukodystrophy.

Authors:  Neha P Godbole; Reza Sadjadi; Madeline A DeBono; Natalie R Grant; Daniel C Kelly; Peter F James; Christopher D Stephen; M David Balkwill; Richard F Lewis; Florian S Eichler
Journal:  Front Neurol       Date:  2021-06-17       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.